[Beacon Staff]

EHA 2015 annual meeting abstracts

by Beacon Staff on Wed Jun 10, 2015 2:57 pm

Hi everyone,

The 2015 annual meeting of the European Hematology Association (EHA) will be starting in just a couple of days. We're still wrapping up lists of all the myeloma-related presentations and posters that will be presented at the meeting, but we thought you might like a look at what we've got so far.

Here are the lists that we've finished, or nearly finished), as of today:

Oral presentations
Poster presentations - Day 1 (Friday, June 12)
Poster presentations - Day 2 (Saturday, June 13)

You can find links to these pages in the sidebar, as well.

As has been the case in the past, there is a good amount of overlap between the ASCO and EHA oral presentations. This is less the case with the poster presentations simply because EHA has many more myeloma-related poster presentations than the ASCO meeting.

As has been the case with the list of abstracts we created for the recent ASCO meeting, we'll add links to actual presentations and posters from the EHA meeting as we get them.

Are there any abstracts in the lists that you find particularly interesting?

[Mark11]

Re: EHA 2015 annual meeting abstracts

by Mark11 on Wed Jun 10, 2015 4:27 pm

I thought this study that Dr. Kapoor did was interesting since I am in the small group of myeloma patients that was diagnosed at less than 50 years old. Interesting that OS (overall survival) from first relapse for younger patients has not improved in the more recent time period (2006-2011) as compared to 2000 to 2005. Good to see the improvement for older patients.

"Although overall survival from diagnosis is superior for young patients with multiple myeloma compared to the elderly, outcomes from first relapse for the 2 age groups are similar in recent period (2006-2011). While this observation may be attributed to improved survival in the elderly at relapse, likely related to increased use of novel agents at relapse, our results also underscore that disease course for young patients is not different than that of the elderly after first relapse, indicating that our current approaches for the young patients with multiple myeloma require substantial improvement."

http://learningcenter.ehaweb.org/eha/2015/20th/100801/prashant.kapoor.post.relapse.outcomes.in.young.patients.with.multiple.myeloma.html

[Mark11]

Re: EHA 2015 annual meeting abstracts

by Mark11 on Wed Jun 10, 2015 4:35 pm

I also thought this meta analysis of clinical trials showing the importance of achieving MRD negative status was interesting as well. PFS (progression free survival) is 37% for MRD negative patients at 8 years compared to 7% that were MRD positive.

"MRD-negativity reduced the odds of death by 59% (OR 0.41; 95% CI 0.26–0.63; P < 0.0001); median OS was not reached for MRD-negative patients versus 82 months for MRD-positive patients. OS was higher for MRD-negative patients versus MRD-positive patients at 3-years (93% vs 79%) and 5-years (78% vs 60%). Presence of MRD was predictive of outcome in patients with adverse cytogenetic profles."


"These results show that MRD negativity, as determined by various high-sensitivity methods, predicted for substantially better PFS and OS in patients with multiple myeloma who had achieved CR. Furthermore, nearly all MRD-positive patients had disease progression within 8 years, whereas a third of MRD-negative patients remained progression-free. This large cohort, meta-analysis confirms that MRD status is a crucial marker of long-term outcomes in patients with multiple myeloma. It is, therefore, a key endpoint in multiple myeloma clinical trials and clearly also has an important role as a surrogate marker of OS."

http://learningcenter.ehaweb.org/eha/2015/20th/101343/nikhil.munshi.significant.impact.of.minimal.residual.disease.%28mrd%29.status.on.html